All the news Showing 10 of 693 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment for people who use drugs Conditional cash transfers may improve HCV screening and treatment in drug users Keith Alcorn / 22 January 2019 Conditional cash transfers – giving money to encourage use of services – may be needed to reach drug users for hepatitis C testing and treatment if they are either unaware of hepatitis ... Treatment for people who use drugs Barriers to HCV treatment access from the drug user's point of view: stigma, complex lives and damaged veins Keith Alcorn / 16 January 2019 Despite access to hepatitis C treatment, many people who inject drugs still perceive numerous barriers to starting treatment, including the attitudes of healthcare workers, the difficulty of juggling treatment with competing demands, a ... International policy Lancet commission sets agenda for the elimination of viral hepatitis Keith Alcorn / 10 January 2019 Viral hepatitis leads to around 1.3 million deaths a year, approximately 257 million people are living with hepatitis B virus (HBV) and 71 million with hepatitis C virus (HCV). Viral hepatitis ... Antiviral therapy Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year Liz Highleyman / 08 January 2019 Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ... Treatment for people living with HIV and HCV Co-infection with HIV and HCV does not increase the risk of end-stage liver disease or liver cancer Keith Alcorn / 04 January 2019 People with HIV and hepatitis C are no longer at higher risk of end-stage liver disease than people with hepatitis C alone, and the trend is probably associated with the improved effectiveness ... NAFLD Aramchol reduces liver fat in people with NASH Liz Highleyman / 02 January 2019 A novel type of experimental therapy led to a significant reduction in liver fat and improvement in liver health among people with non-alcoholic steatohepatitis (NASH), according to study presented at the recent AASLD Liver ... Antiviral therapy Hepatitis B capsid assembly modulators show good antiviral activity Liz Highleyman / 21 December 2018 Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ... NAFLD Lean people can develop fatty liver disease Liz Highleyman / 17 December 2018 Metabolically healthy lean people may develop non-alcoholic fatty liver disease (NAFLD), although this is much more common among people with obesity and metabolic abnormalities, according to research presented at the AASLD Liver ... Hepatitis C elimination Hepatitis C rates in US track the opioid epidemic Liz Highleyman / 14 December 2018 Nearly 2.4 million people in the United States are living with active hepatitis C virus (HCV) infection, according to the latest data from the US Centers for Disease Control and Prevention (CDC). ... NAFLD Burden of severe liver disease due to fatty liver will more than double by 2030 Keith Alcorn / 07 December 2018 If current trends in obesity and diabetes continue, at least 520 million people will be living with non-alcoholic fatty liver disease (NAFLD) in western Europe, China, Japan and the United States by ... ← First12345...70Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds